FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for relapsed/refractory multiple myeloma

The Oncology Drugs Advisory Committee voted 12-0 in favour of approving this treatment on the basis of the results of the pivotal DREAMM-2 study. This IgG1 monoclonal antibody-drug conjugate is currently under accelerated assessment in the EU.


Biospace Inc.